Analysis of soluble angiogenic factors in Crohn's disease: A preliminary study

Gastroenterologia y Hepatologia

Volumn 30, Issue 9, 2007, Pages 518-524

  Pousa, Inés Dueñas ^a   Jiménez, José Maté ^a   Mora, Xamila Salcedo ^a   Abreu, Maria T ^b   Otero, Ricardo Moreno ^a   Gisbert, Javier P ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Playa de Mojacar   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY DISEASE; INTESTINAL FIBROSIS; INTESTINE FISTULA; INTESTINE STENOSIS; MALE; PHENOTYPE;

EID: 36048966935     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13111682     Document Type: Article

References (23)

1. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55 Suppl 1:1-15.
2. Gisbert JP, González-Lama Y, Mate J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol. 2007;30:117-29.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-60.
4. Pousa ID, Gisbert JP, Mate J. Vascular development in inflammatory bowel disease. Gastroenterol Hepatol. 2006;29:414-21.
5. Beat A, Imhof MA-L. Angiogenesis and inflammation face off. Nat Med. 2006;12:171-2.
6. Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martin-Vilchez S, Moreno-Otero R. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther. 2005;22:23-30.
7. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology. 2004;39:1185-95.
8. Ranieri G, Ria R, Roccaro AM, Vacca A, Ribatti D. Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2005;4:13-22.
9. Danese S, Sans M, De la Motte C, Graziani C, West G, Phillips MH, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060-73.
10. Konno S, Iizuka M, Yukawa M, Sasaki K, Sato A, Horie Y, et al. Altered expression of angiogenic factors in the VEGF-Ets-1 cascades in inflammatory bowel disease. J Gastroenterol. 2004;39:931-9.
11. Kader HA, Tchernev VT, Satyaraj E, Lejnine S, Kotler G, Kingsmore SF, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005;100:414-23.
12. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-8.
13. Magro F, Araujo F, Pereira P, Meireles E, Diniz-Ribeiro M, Velosom FT. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1265-74.
14. Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest. 2006;36:127-32.
15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170 Suppl:2-6.
16. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med. 2003;9:936-43.
17. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1:1356-70.
18. Bousvaros A, Leichtner A, Zurakowski D, Kwon J, Law T, Keough K, et al. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci. 1999;44:424-30.
19. Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol. 1998;33:504-8.
20. Kapsoritakis A, Sfiridaki A, Maltezos E, Simopoulos K, Giatromanolaki A, Sivridis E, et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis. 2003;18:418-22.
21. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15:102-11.
22. Hangai M, Murata T, Miyawaki N, Spee C, Lim JI, He S, et al. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:1617-25.
23. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood. 2003;102:1506-14.